English | Español

Eli Lilly And Company
Patient Daily | May 25, 2023

Lilly ESG Report Highlights Progress Towards Sustainability Goals
Patient Daily | May 24, 2023

Lilly's peresolimab Phase 2a rheumatoid arthritis trial published in The New England Journal of Medicine
Patient Daily | May 22, 2023

Loxo@Lilly Announces Details of Presentations at 2023 European Hematology Association (EHA) Annual Meeting
Patient Daily | May 9, 2023

Lilly Provides $500,000 in Grants to Support Equitable Access to Education for Dreamers in Indiana
Patient Daily | May 9, 2023

Lilly Declares Second-Quarter 2023 Dividend
Patient Daily | May 9, 2023

Lilly's tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in SURMOUNT-2
Patient Daily | Apr 26, 2023

Lilly to Divest BAQSIMI to Amphastar
Patient Daily | Apr 26, 2023

Lilly to Make Record-Breaking Investment in Indiana Manufacturing Facilities

Trending
+ Pharmaceuticals
Patient Daily | May 28, 2025

University of California medical researcher: ‘The 340B program is not associated with an improvement in mortality for low-income patients'
+ Pharmaceuticals
Patient Daily | May 29, 2025

Executive director of COA on 340B reform: ‘Start with PBMs then mega hospitals that pocket 340B discounts’
+ Pharmaceuticals
Patient Daily | Jun 2, 2025

PathAI collaborates with Northwestern Medicine on digital pathology advancements
+ Pharmaceuticals
Patient Daily | May 27, 2025

New study shows effectiveness of recent RSV prevention strategies